Overview

The seriousness of the diagnosis of cancer challenges the capacity to survive, sets a course in life, and dashes hopes and dreams. Over the 20th century, even as cancer treatments improved and some patients were cured, psychiatrists in the tradition of humane psychiatry used their skills to stand by patients who were overwhelmed and helped them make complex treatment choices by which they could shape the rest of their lives or their end-of-life care. Psychiatrists have offered expert diagnosis and management of co-morbid psychiatric syndromes and collaborated with oncologists so that treatable psychiatric illnesses have not stood in the way of oncologic care. Specific cancer-related or cancer treatment-related neuropsychiatric syndromes ( Table 31-1 ) can, and should, be recognized and treated. Additionally, psychiatrists can help patients to cope with physical symptoms, developmental losses, changes in relationships, and the effects of cancer on families.

Table 31-1
Neuropsychiatric Side Effects of Cancer Drugs

Hormones

Anti-estrogens

  • Tamoxifen, toremifene : hot flashes, insomnia, mood disturbance; at high doses tamoxifen can cause confusion

  • Anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) : hot flashes, fatigue, mood swings, and irritability; cognitive effects are not known

  • Raloxifene (Evista ): no cognitive side effects noted

  • Leuprolide (Lupron), goserelin (Zoladex) : hot flashes, fatigue, and mood disturbance

Androgen Blockade

  • Leuprolide (Lupron), goserelin (Zoladex) : hot flashes, fatigue, and mood disturbance

  • Flutamide (Eulexin), bicalutamide (Casodex), nilutamide (Nilandron) : as above

Glucocorticoids

  • Dose-related, variable psychiatric side effects including insomnia, hyperactivity, hyperphagia, depression, hypomania, irritability, and psychosis

  • Treated by ad hoc antipsychotics easily with cancer patients

  • Other drugs with benefit: lithium, valproate, lamotrigine, and mifepristone

  • Dexamethasone (Decadron) 9 mg equals 60 mg of prednisone; psychiatric side effects are associated with this dose level

  • Steroids used as part of an antiemetic treatment with chemotherapy infusion, with lymphoma protocols as high as prednisone 100 mg for 5 days, with nervous system radiation treatment to reduce swelling, with taxanes to reduce side effects

Biologicals

Interferon-α

  • Depression, cognitive impairment, hypomania, psychosis, fatigue, and malaise

  • Responsive to antidepressants, hypnotics, antipsychotics, stimulants, and antianxiety agents

  • Associated with autoimmune thyroiditis that may increase or decrease thyroxine; check thyroid function

  • May inhibit metabolism of some antidepressants by P450 enzymes CYP1A2, CYP2C19, CYP2D6

  • Interferon-β has less neurotoxicity

Interleukin-2

  • Delirium, flu-like syndrome, dose-dependent neurotoxicity, and hypothyroidism

Chemotherapy

Vincristine (Oncovin), vinblastine (Velban), vinorelbine (Navelbine)

  • Neurotoxicity is dose-related and usually reversible. Fatigue and malaise are noted. Seizure and SIADH are uncommon. Postural hypotension may be an aspect of autonomic neuropathy

  • Less toxicity is noted with vinblastine and vinorelbine

Procarbazine (Matulane)

  • Mild reversible delirium

  • A weak MAO inhibitor

  • Antidepressant use must consider the timing of procarbazine or risk serious interactions

  • Disulfiram-like effect; avoid alcohol

Asparaginase (Elspar)

  • Depression, lethargy, and delirium with treatment

Cytarabine (ARA-cell, Alexin)

  • High-dose IV treatment (over 18 g/m 2 per course) can cause confusion, obtundation, seizures, and coma, cerebellar dysfunction, and leukoencephalopathy. Older patients with multiple treatments are more susceptible. Delirium and somnolence can be seen 2–5 days into treatment. Those with renal impairment are more vulnerable

Fludarabine (Fludara)

  • Rare somnolence, delirium, and rare progressive leukoencephalopathy

5-Fluorouracil (5-FU)

  • The primary neurotoxicity is cerebellar, but encephalopathy with headache, confusion, disorientation, lethargy, and seizures has also been seen

  • Rare deficiency of enzyme that metabolizes dihydropyrimidine dehydrogenase (DPD) is associated with greater exposure and more toxicity

  • Fatigue is the most common side effect

  • Cerebellar syndrome and rarely seizure or confusion or parkinsonism may be noted

  • High-dose IV thymidine may be an antidote for toxicity

Capecitabine (Xeloda)

  • Related to 5-FU, but with less neurotoxicity

Methotrexate

  • Causes neurotoxicity particularly when the route is intrathecal or high-dose IV (usually over 1 g/m 2 ). The toxicity, which is usually reversible, is related to peak level and duration of exposure. Leptomeningeal disease or other conditions that break the blood–brain barrier may impair drug clearance. Prolonged exposure allows the drug to pass through the ependyma of the ventricles to cause leukoencephalopathy. The risk is greater in patients also exposed to cranial radiation. Intrathecal methotrexate may also cause seizures, motor dysfunction, chemical arachnoiditis, and coma. Serum levels are followed closely; folinic acid (leucovorin) rescue is an antidote. Alkalinization may lower the serum level

  • There is a dose- and route-related risk of delirium

Pemetrexed (Alimta)

  • An anti-folate given with supplements of folate, intramuscular vitamin B 12 , and dexamethasone. It is associated with a 10% rate of depression and fatigue

Gemcitabine (Gemzar)

  • Fatigue, flu-like syndrome, and a rare autonomic neuropathy

Etoposide (Eposin)

  • Postural hypotension and rare disorientation

Carmustine (BCNU)

  • Delirium, only at high doses, rare leukoencephalopathy

Thiotepa

  • Rare leukoencephalopathy

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here